Hedgehog signaling pathway: a novel target for cancer therapy: vismodegib, a promising therapeutic option in treatment of basal cell carcinomas.
Hedgehog signaling pathway: a novel target for cancer therapy: vismodegib, a promising therapeutic option in treatment of basal cell carcinomas.
复制标题
DOI：
10.4103/0253-7613.124884
复制
发表时间：
2014-01
影响因子：
2.4
通讯作者：
Abidi A
中科院分区：
文献类型：
--
作者：
Abidi A
Hedgehog信号通路是胚胎发生和早期发育过程中细胞生长和分化的主要调节因子之一。它在成人中主要是静止的，但该途径的不适当突变或失调与癌症的发展有关。因此，最近它已被认为是癌症的新治疗靶点。基底细胞癌（BCC）和髓母细胞瘤是两种最常见的癌症，它们被鉴定为hedgehog通路的组成部分发生突变。靶向Hedgehog通路抑制剂的发现在临床试验中显示出有希望的结果，其中一些仍在进行临床评估。Vismodegib（GDC-0449）是一种口服刺猬信号通路抑制剂，在临床开发中已达到最远。在基底细胞癌和髓母细胞瘤中的初步临床试验显示出良好的疗效和安全性，因此被美国FDA批准用于晚期基底细胞癌。本文综述了hedgehog通路在不同类型的人类癌症中的激活的分子基础和现有知识，以及新型药物vismodegib的现状和未来前景。
The Hedgehog signaling pathway is one of the major regulators of cell growth and differentiation during embryogenesis and early development. It is mostly quiescent in adults but inappropriate mutation or deregulation of the pathway is involved in the development of cancers. Therefore; recently it has been recognized as a novel therapeutic target in cancers. Basal cell carcinomas (BCC) and medulloblastomas are the two most common cancers identified with mutations in components of the hedgehog pathway. The discovery of targeted Hedgehog pathway inhibitors has shown promising results in clinical trials, several of which are still undergoing clinical evaluation. Vismodegib (GDC-0449), an oral hedgehog signaling pathway inhibitor has reached the farthest in clinical development. Initial clinical trials in basal cell carcinoma and medulloblastoma have shown good efficacy and safety and hence were approved by U.S. FDA for use in advanced basal cell carcinomas. This review highlights the molecular basis and the current knowledge of hedgehog pathway activation in different types of human cancers as well as the present and future prospects of the novel drug vismodegib.
登录
查看更多内容
影响因子：
5.7
作者：
Feldmann G;Fendrich V;McGovern K;Bedja D;Bisht S;Alvarez H;Koorstra JB;Habbe N;Karikari C;Mullendore M;Gabrielson KL;Sharma R;Matsui W;Maitra A
通讯作者：
Maitra A
影响因子：
11.5
作者：
Berlin, Jordan;Bendell, Johanna C.;Low, Jennifer A.
通讯作者：
Low, Jennifer A.
影响因子：
11.5
作者：
Kaye, Stanley B.;Fehrenbacher, Louis;Reddy, Josina C.
通讯作者：
Reddy, Josina C.
影响因子：
56.9
作者：
Rohatgi, Rajat;Milenkovic, Ljiljana;Scott, Matthew P.
通讯作者：
Scott, Matthew P.
影响因子：
4.3
作者：
Lauth, Matthias;Toftgard, Rune
通讯作者：
Toftgard, Rune